Divi's Labs Q4 net profit up 33%, total income stands at Rs 1,466 cr

The company had posted a net profit of Rs 291.97 crore for the same period previous fiscal, Divi's Labs said in a BSE filing

Drugs, Pharma, medicine
For the last fiscal, its total income stood at Rs5,584.05 crore. It was Rs 5,101.89 crore in the previous fiscal, it added.
BS Web TeamAgencies New Delhi
1 min read Last Updated : Jun 06 2020 | 5:41 PM IST
Drug firm Divi's Laboratories on Saturday reported a 32.96 per cent rise in its consolidated net profit to Rs 388.23 crore for the quarter ended March 31, 2020.

The company had posted a net profit of Rs 291.97 crore for the same period previous fiscal, Divi's Labs said in a BSE filing.

Consolidated total income of the company stood at Rs 1,466.44 crore for the quarter under consideration. It was Rs 1,307.97 crore for the same period year ago.


Net profit for the fiscal year ended March stood at Rs 1,376.54 crore as against Rs 1,352.74 crore in the previous fiscal, Divi's Labs said.

For the last fiscal, its total income stood at Rs5,584.05 crore. It was Rs 5,101.89 crore in the previous fiscal, it added.

The company's board has declared and paid an interim dividend of Rs 16 per share for the financial year 2019-20. No final dividend is recommended. The total dividend payout for the current year amounted to Rs 512.06 crore including dividend tax,Divi's Labs said.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Divi's LaboratoriesDivi's Labs Q4 net profit

Next Story